gemcitabine + oxaliplatin + lenvatinib + toripalimab

A combination regimen composed of four distinct anticancer agents: **gemcitabine**, **oxaliplatin**, **lenvatinib**, and **toripalimab**. - **Gemcitabine** is a nucleoside metabolic inhibitor (antimetabolite) that inhibits DNA synthesis by incorporation into DNA, leading to DNA chain termination and apoptosis of proliferating tumor cells. It is used in a variety of solid tumors, including pancreatic, ovarian, lung, and breast cancers[7]. - **Oxaliplatin** is a third-generation platinum-based alkylating agent that forms DNA crosslinks, inhibiting DNA replication and transcription, which results in cell death. It is commonly used for colorectal, pancreatic, and other cancers[6]. - **Lenvatinib** is a small molecule multi-kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. By inhibiting these kinases, lenvatinib suppresses angiogenesis and tumor growth (noted from general knowledge; not cited directly). - **Toripalimab** is a humanized monoclonal antibody that targets the immune checkpoint programmed cell death protein 1 (**PD-1**), blocking interaction with its ligands PD-L1 and PD-L2, and thereby promoting immune-mediated tumor cell death (noted from general knowledge; not cited directly). This quadruple combination likely aims to maximize antitumor efficacy by integrating cytotoxic chemotherapy (DNA damage and antimetabolite effects), anti-angiogenesis, and immune checkpoint inhibition. Clinical trials may be ongoing in advanced solid tumors, but the specific combination is not currently an approved standard therapy.

Brand names

LoqtorziTuoyi

Other names

toripalimab-tpziTAB-001TAB001TAB 001